In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 26 to 50 of 387

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance	TBC
Atogepant for treating migraine [ID6615]	Technology appraisal guidance	30 June 2026
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance	TBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]	Technology appraisal guidance	TBC
Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]	Technology appraisal guidance	TBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance	TBC
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]	Technology appraisal guidance	TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]	Technology appraisal guidance	TBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]	Technology appraisal guidance	14 April 2027
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]	Technology appraisal guidance	TBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]	Technology appraisal guidance	TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance	TBC
Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]	Technology appraisal guidance	10 March 2027
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance	18 November 2026
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]	Technology appraisal guidance	26 August 2026
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019
Bipolar disorder: assessment and management (extraordinary review)	NICE guideline	TBC
Bladder cancer: diagnosis and management (update)	NICE guideline	TBC
Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma	HealthTech guidance	TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance	TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC

Results per page

10
25
50
All